QTPlus‐AM21 further showed enhanced antitumor immunity when systemically administered in combination with atezolizumab (ATZ), an anti‐PD‐L1 therapy, with a significant increase of antitumor immune cell populations in TME, suggesting that QTPlus‐AM21 would not only be a strong antitumor candidate directly targeting tumor cells but also be a promising immunomodulatory agent to potentiate antitumor immunity. This evidence concerns the gene CD274 and neoplasm.